

## Clinimetric Testing of the Comprehensive Cervical Dystonia Rating Scale

Cynthia L. Comella MD,<sup>1\*</sup> Joel S. Perlmutter, MD,<sup>2</sup> Hyder A. Jinnah, MD, PhD,<sup>3</sup> Tracy A. Waliczek, AS,<sup>1</sup> Ami R. Rosen, MS, CGC,<sup>3</sup> Wendy R. Galpern, MD,<sup>4</sup> Charles A. Adler, MD, PhD,<sup>5</sup> Richard L. Barbano,<sup>6</sup> Stewart A. Factor, DO,<sup>3</sup> Christopher G. Goetz, MD,<sup>1</sup> Joseph Jankovic, MD,<sup>7</sup> Stephen G. Reich, MD,<sup>8</sup> Ramon L. Rodriguez, MD,<sup>9</sup> William L. Severt, MD, PhD,<sup>10</sup> Mateusz Zurowski, MD, MSc,<sup>11</sup> Susan H. Fox, MB ChB, MRCP, PhD,<sup>11</sup> and Glenn T. Stebbins, PhD<sup>1</sup>

<sup>1</sup>Rush University Medical Center, Chicago, Illinois, USA

<sup>2</sup>Washington University School of Medicine, St. Louis, Missouri, USA

<sup>3</sup>Emory University, Atlanta, Georgia, USA

<sup>4</sup>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

<sup>5</sup>Mayo Clinic, Scottsdale, Arizona, USA

<sup>6</sup>University of Rochester, Rochester, New York, USA

<sup>7</sup>Baylor College of Medicine, Houston Texas, USA

<sup>8</sup>University of Maryland School of Medicine, Baltimore, Maryland, USA

<sup>9</sup>University of Florida Movement Disorders Center, Gainesville, Florida, USA

<sup>10</sup>Beth Israel Medical Center, New York, New York, USA

<sup>11</sup>University of Toronto, University Health Network, Toronto, Ontario, Canada

**ABSTRACT: Introduction:** The aim of this study was to test the clinimetric properties of the Comprehensive Cervical Dystonia Rating Scale. This is a modular scale with modifications of the Toronto Western Spasmodic Torticollis Rating Scale (composed of three subscales assessing motor severity, disability, and pain) now referred to as the revised Toronto Western Spasmodic Torticollis Scale-2; a newly developed psychiatric screening instrument; and the Cervical Dystonia Impact Profile-58 as a quality of life measure.

**Methods:** Ten dystonia experts rated subjects with cervical dystonia using the comprehensive scale. Clinimetric techniques assessed each module of the scale for reliability, item correlation, and factor structure.

**Results:** There were 208 cervical dystonia patients (73% women; age,  $59 \pm 10$  years; duration,  $15 \pm 12$  years). Internal consistency of the motor severity subscale was acceptable (Cronbach's  $\alpha = 0.57$ ). Item to total correlations showed that elimination of items with low correlations ( $<0.20$ ) increased  $\alpha$  to 0.71. Internal con-

sistency estimates for the subscales for disability and pain were 0.88 and 0.95, respectively. The psychiatric screening scale had a Cronbach's  $\alpha$  of 0.84 and satisfactory item to total correlations. When the subscales of the Toronto Western Spasmodic Torticollis Scale-2 were combined with the psychiatric screening scale, Cronbach's  $\alpha$  was 0.88, and construct validity assessment demonstrated four rational factors: motor; disability; pain; and psychiatric disorders. The Cervical Dystonia Impact Profile-58 had an  $\alpha$  of 0.98 and its construction was validated through a confirmatory factor analysis.

**Conclusions:** The modules of the Comprehensive Cervical Dystonia Rating Scale are internally consistent with a logical factor structure. © 2016 International Parkinson and Movement Disorder Society

**Key Words:** cervical dystonia; focal dystonia; rating scale; Toronto Western Spasmodic Torticollis Rating Scale; Cervical Dystonia Impact Profile-58

\*Correspondence to: Cynthia L. Comella, MD, Rush University Medical Center, 1725 West Harrison Street, Suite 755, Chicago, IL 60612, USA; E-mail: ccomella@rush.edu

**Funding agencies:** This study was funded by the National Institutes of Health (NIH) grant NS 065701 from the National Institute of Neurological Disorders and Stroke and the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences, NIH; the Dystonia Medical Research Foundation; and Allergan Inc.

**Relevant conflicts of interest/financial disclosures:** Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

**Received:** 22 September 2015; **Revised:** 13 November 2015; **Accepted:** 13 December 2015

**Published online 12 March 2016 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.26534**

Cervical dystonia (CD) is a complex disorder marked by involuntary movements of neck and shoulders, pain, impaired activities of daily living (ADLs), and reduced quality of life. The abnormal movements often combine head turn, tilt, forward or backward flexion, anterior or sagittal shift, and shoulder elevation.<sup>1,2</sup> The involuntary movements are associated with significant disability. In addition, pain occurs in 75% of patients and contributes to a greater degree of disability.<sup>3</sup> CD has also been associated with psychiatric disorders, including depression, anxiety, panic disorders, and social phobia.<sup>4-7</sup> Furthermore, several studies have also demonstrated impaired health-related quality of life (HRQoL) in CD.<sup>8-14</sup>

Although there have been many rating scales developed for motor symptoms of CD,<sup>15</sup> only three of these, the Tsui scale,<sup>16</sup> the Cervical Dystonia Severity Scale (CDSS),<sup>17</sup> and the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), have had clinimetric evaluation. None of these scales address the psychiatric symptoms or quality of life. The Tsui rating scale is a six-item scale that assesses amplitude and duration of involuntary neck movements, shoulder elevation, and head tremor.<sup>16</sup> This scale is designed to assess head and shoulder postures and head tremor, but does not take into account the other manifestations of CD. The CDSS uses a protractor and wall chart to rate angles of head deviation from neutral in each of three planes.<sup>17</sup> This scale does not evaluate shoulder elevation, tremor, or sagittal shift. The Tsui rating scale and CDSS do not address pain, ADLs, psychiatric symptoms, or quality of life.

The standard TWSTRS consists of three domains that assess motor severity, pain, and disability.<sup>18</sup> The motor severity subscale consists of 10 items, with variable scaling and weighting. It also includes a disability scale with six items, and a pain scale with three items. The total score is the sum of each of the subscales. Only the motor domain has undergone evaluation for inter-rater reliability and construct validity, with good to excellent inter-rater reliability.<sup>19</sup> Despite the limited clinimetric studies of the TWSTRS, it has been used extensively in clinical studies of CD and is the scale currently recommended by the International Parkinson and Movement Disorder Society (MDS) Task Force on Dystonia Rating Scales.<sup>15</sup>

There are no psychiatric rating scales validated for use in CD. Whereas the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria are the gold standard for diagnosis of psychiatric disease; their application requires specific training and is impractical for routine use by most CD providers. There are several self-administered scales that are easy to administer, require no examiner training, and have been assessed for clinimetric properties in primary depression and anxiety. The Beck Depression

Inventory<sup>20</sup> is a self-administered scale with 21 components that takes 10 to 15 minutes to complete. This scale does not emphasize somatic components and therefore avoids the confounding factors of the movement associated with CD.<sup>21</sup> The Hospital Anxiety and Depression Rating Scale is a self-administered scale that consists of 14-item subscales for both depression and anxiety.<sup>22,23</sup> This scale was specifically developed for use in patients with somatic comorbidity and has no questions related to the physical signs of depression or anxiety. The Beck Anxiety Index is a self-reported scale<sup>21</sup> designed as a screening tool for anxiety with good positive predictive value for panic disorders.<sup>24</sup> Although these psychiatric rating scales are all well validated in psychiatric practice, they have not been systematically applied to CD.

The effect of CD on quality of life is comparable to that seen in multiple sclerosis, Parkinson's disease, stroke<sup>14</sup> and other chronic diseases.<sup>25</sup> Standard measures of QOL, including generic HRQoL,<sup>25</sup> EuroQoL, 36-item Short Form (SF-36), and Rosenbergs' self-esteem scale<sup>26</sup> are not consistent in identifying factors predicting reduced quality of life in CD and do not correlate with effective treatment for CD, such as botulinum toxin injections.<sup>12,27</sup> The Craniocervical Dystonia Questionnaire, although designed specifically for blepharospasm and CD, has not been extensively used or tested against other scales.<sup>28</sup> The Cervical Dystonia Impact Profile-58 item (CDIP-58) was developed using a modified Delphi method with Rasch methodology.<sup>29</sup> It is a self-administered scale with eight subscales measuring the impact of head and neck symptoms on a variety of quality-of-life items.<sup>29</sup> The CDIP-58 has been evaluated for reliability and validity in CD<sup>30</sup> and shown to be superior to the SF-36, a widely used but generic quality-of-life measure. The CDIP-58 also demonstrates sensitivity to change after botulinum toxin injections<sup>29,31</sup> and is the recommended scale for quality of life in CD.<sup>15</sup>

In this study, the original TWSTRS was revised to the TWSTRS-2 to address identified deficiencies, including the variable scaling of items, the lack of an item for head tremor, and the weighting of the duration factor by 2.<sup>32</sup> The TWSTRS-PSYCH was developed to screen for psychiatric disorders associated with CD. The CDIP-58 with previously established reliability and validity was included in its original form. We combined the TWSTRS-2, TWSTRS-PSYCH, and CDIP-58 to produce the modular Comprehensive Cervical Dystonia Rating Scale (CCDRS). The specific aim of the study was to assess the reliability and construct validity of the CCDRS.

## Materials and Methods

The methods for development of the CCDRS have been described in a previous publication.<sup>32</sup> Briefly, the

existing TWSTRS motor severity was revised to the TWSTRS-2 motor severity using a modified Delphi method with input from dystonia experts. The TWSTRS-PSYCH was developed using a similar methodology with input from psychiatrists, dystonia experts, and patients. The draft TWSTRS-2 included assessments for motor severity (12 items), pain (five items), and disability (six items). The TWSTRS-PSYCH included six items rated on a 5-point scale from 0 (absent) to 4 (severe) for occurrence over the past month. The maximal score of the TWSTRS-PSYCH was 24. The CDIP-58 includes 58 self-administered questions that define eight subscales and are transformed into a total score, with a maximal score of 100. The TWSTRS-2, TWSTRS-PSYCH, and CDIP-58 then were combined into the CCDRS and used in the data collection phase of the study along with other demographic and disease-related measures.

Subjects with isolated CD, previously known as primary dystonia, were recruited from 10 sites. Demographic information, including age, sex, and duration of CD, were collected. For this study, subjects were videotaped using a standardized protocol during the time that the site investigator rated the subject severity using the TWSTRS-2 motor severity subscale.<sup>32</sup> Subjects were interviewed to complete the TWSTRS-2 disability and pain subscales, as well as the TWSTRS-PSYCH. The subjects completed the self-reported CDIP-58.

There are no accepted formulae for calculating required sample sizes for scale validation studies, particularly factor analytic methods, at given levels of power.<sup>33</sup> Instead, recommended subject-to-item ratios are employed. For the present study, we have a 9.1:1 subject-to-item ratio, which exceeds the recommended 8:1 ratio shown to be adequate for this analysis.<sup>34,35</sup>

Rating scores and video were electronically sent to a central database at Washington University (St. Louis, MO).<sup>36</sup> The video and data were assessed for completeness. Queries regarding missing data were resolved. Accuracy of the data entry was verified through cross-referencing electronic data to paper data collection forms in 10% of cases.

### Statistical Analysis

Subject demographics and disease-related variables were examined using frequency counts and measures of central tendency and variability, as appropriate. To assess the reliability and validity of the TWSTRS-2 and TWSTRS-PSYCH components of the CCDRS, we employed both Classical Test Theory (CRT) and Item Response Theory (IRT). CRT focuses on the relationships of individual items to the entire scale,<sup>37</sup> whereas IRT focuses on the measurement characteristics of the items in relation to the individual completing the scale.<sup>37</sup> Using CRT, we examined Cronbach's alpha, a measure of scale reliability, item-to-total correlations,

changes in alpha if selected items were removed, and distributional skewness, a measure of potential floor or ceiling effects, for the separate subscales of the TWSTRS-2 (motor severity, disability, and pain) and TWSTRS-PSYCH modules of the CCDRS. These analyses were conducted using SPSS software (version 21; SPSS, Inc., Chicago, IL). Additionally, we examined the construct validity through exploratory factor analyses. Because of the ordered categorical level of measurement of the CCDRS, we employed an unweighted least squares approach for the factor estimate and a CF-Varimax orthogonal rotation to improve the interpretability of the factors. MPlus (version 7) was used for these analyses. For the IRT approach, we used a graded response model analysis with maximum likelihood parameter estimation<sup>38</sup> to examine item discrimination, or the strength of the relationship between the item and the measured domain, and item threshold, or the level of item response to the overall severity of the measured domain. MPlus (version 7) was used for these analyses.

To assess each item's utility in the CCDRS, we identified items with low item-to-total correlations (defined as  $\leq 0.3$ ), improvement in Cronbach's alpha if omitted, low factor loading (defined as  $\leq 0.4$ ), a skewness outside of the range  $-1.50$  to  $+1.50$  representing possible floor or ceiling effects, nonsignificant IRT discrimination scores and thresholds that did not encompass a value of zero. Based on this assessment, each item was considered either as 1 to keep in the scale or as 1 to drop or modify. If an item met the criteria for acceptable item-to-total correlation, change in alpha if the item were omitted, appropriate factor loading, skewness, and IRT discrimination and threshold, it was retained. Items not meeting these criteria were deleted.

Because the CDIP-58 module of the CCDRS had already undergone clinimetric examination for reliability and validity, we limited our analysis to assessments of internal consistency (Cronbach's alpha) and confirmatory factor structure (CFA). The CFA was conducted to determine if the 8 factors found in the original publication<sup>29</sup> could be confirmed with the data collected for this study. We evaluated the CFA results based on the Comparative Fit Index (CFI).<sup>39</sup> To confirm a good fit between the original factor structure and our data, the CFI was required to be 0.90 or greater. Mean and variance adjusted weighted least square estimator was used to confirm model fit. We also used the root mean square error of approximation (RMSEA) to check the goodness of fit, with values less or equal than 0.10 indicating an acceptable index. MPlus (version 7) was used for these analyses.

## Results

A total of 208 CD subjects (73% women; mean age: 59 years; standard deviation [SD]:  $\pm 9.95$ ), onset of

**TABLE 1.** Classical test theory and item response analyses results for items on the TWSTRS-2 Motor, TWSTRS-2 Disability, TWSTRS-2 Pain, and TWSTRS-2 Psych components of the CCDRS

Item	Item-Total Correlation	Alpha-if-Item-Removed	Factor Loading	Skewness	IRT Discrimination (P Value)	IRT Threshold (Min; Max)	Action
<b>TWSTRS-2 Motor</b>							
Rotation	0.314	No increase	0.420	0.314	1.00 (<0.0005)	-2.75; 2.50	Keep
Laterocollis	0.466	No increase	0.519	0.608	1.40 (<0.0005)	-2.21; 6.22	Keep
Anterocollis	0.180	Increased	<0.3	1.780	0.69 (0.06)	0.68; 3.53	Drop/modify
Retrocollis	0.091	Increased	<0.3	1.536	0.17 (0.44)	0.62; 5.31	Drop/modify
Lateral Shift	-0.068	Increased	<0.3	1.723	-0.24 (0.19)	0.71; 5.35	Drop/modify
Sagittal Shift	0.136	Increased	<0.3	1.575	0.34 (0.05)	0.45; 5.37	Drop/modify
Head Tremor	0.000	Increased	<0.3	0.472	0.04 (0.84)	-0.59; 3.91	Drop
Shoulder Elevation	0.349	No increase	0.481	0.542	1.11 (<0.0005)	-1.79; 2.88	Keep
Duration	0.527	No increase	0.626	-0.648	1.58 (<0.0005)	-6.53; 1.06	Keep
Sensory Trick	0.011	Increased	<0.3	1.107	0.09 (0.63)	-1.42; 2.23	Drop/modify
ROM	0.373	No increase	0.428	0.877	1.16 (<0.0005)	-1.81; 3.88	Keep
Time in Midline	0.472	No Increase	0.631	-0.563	1.60 (<0.0005)	-1.59; 0.49	Keep
<b>TWSTRS-2 Disability</b>							
Work	0.722	No increase	0.704	0.483	1.00 (<0.0005)	-1.46; 5.50	Keep
ADL	0.654	No increase	0.604	0.774	1.66 (<0.0005)	-0.77; 5.45	Keep
Driving	0.587	No increase	0.542	0.294	1.40 (<0.0005)	-1.90; 5.13	Keep
Reading	0.748	No increase	0.805	0.183	3.32 (<0.0005)	-3.00; 8.12	Keep
Television	0.734	No increase	0.759	-0.052	3.35 (<0.0005)	-2.92; 6.80	Keep
Outside of Home	0.728	No increase	0.690	0.685	2.22 (<0.0005)	-2.00; 5.91	Keep
<b>TWSTRS-2 Pain</b>							
Pain Best	0.778	No increase	0.752	1.13	1.000 (<0.0005)	-0.11; 2.92	Keep
Pain Worst	0.884	No increase	0.848	-0.210	4.853 (<0.0005)	-1.20; 0.96	Keep
Pain Usual	0.944	No increase	0.900	0.312	6.169 (<0.0005)	-0.77; 1.87	Keep
Pain Duration	0.835	No increase	0.778	-0.169	3.564 (<0.0005)	-1.130; 0.55	Keep
Pain Disability	0.735	No increase	0.669	0.472	2.320 (<0.0005)	-0.50; 1.74	Keep
<b>TWSTRS-2 Psych</b>							
Depression	0.657	No increase	0.724	0.557	1.00 (<0.0005)	-0.44; 2.38	Keep
Loss of Interests	0.673	No increase	0.740	1.263	2.20 (<0.0005)	0.22; 2.08	Keep
Discomfort in Public	0.570	No increase	0.627	0.728	1.57 (<0.0005)	-0.17; 2.34	Keep
Anxiety	0.672	No increase	0.741	0.907	2.04 (<0.0005)	-0.22; 2.24	Keep
Panic	0.559	No increase	0.626	3.646	2.37 (<0.0005)	1.18; 2.57	Keep
Afraid Going Out	0.576	No increase	0.645	2.673	2.16 (<0.0005)	0.93; 2.85	Keep

Item-To-Total = correct item score to total score correlation; Alpha-If-Item-Removed = increase or decrease in Cronbach's alpha if the item is removed from the analysis; Factor Loading = maximum factor loading value; Skewness = a measure of distributional asymmetry; IRT Discrimination = strength of relationship between item and the measured construct; IRT Threshold = level of item response in relation to severity of measured construct, minimum and maximum thresholds displayed.

CD 44 years (SD, ± 12.11) from 10 sites in the United States were included. Mean severity of CD as measured using the TWSTRS 2 total score was (33.24; SD, ± 13.22), with subscale scores for motor severity of (16.29; SD, ± 5.54), disability (9.21; SD, ± 5.72), and pain (7.88; SD, ± 5.56).

### TWSTRS-2 Motor Severity Subscale

Overall Cronbach's alpha for the TWSTRS-2 motor severity subscale was 0.57 (Table 1). Items assessing Rotation, Laterocollis, Shoulder Elevation, Duration, Range of Motion, and Time in Midline met criteria for acceptable item-to-total correlation, change in alpha if item omitted, factor loading, skewness, IRT discrimination, and IRT threshold. Items assessing anterocollis, retrocollis, lateral shift, sagittal shift, head tremor, and effect of a sensory trick failed to

meet the criteria for utility in the CCDRS and were deleted from the CCDRS.

### TWSTRS-2 Disability Subscale

Overall Cronbach's alpha for the TWSTRS-2 disability subscale was 0.88 (Table 1). Items assessing Work, Activities of Daily Living, Driving, Reading, Television, and Outside of Home Disability met criteria for acceptable item-to-total correlation, change in alpha if item omitted, factor loading, skewness, IRT discrimination, and IRT threshold. All items met the criteria for utility in the CCDRS and were retained in the CCDRS.

### TWSTRS-2 Pain Subscale

Overall Cronbach's alpha for the TWSTRS-2 pain subscale was 0.95 (Table 1). Items assessing Pain at its

Best, Pain at its Worst, Usual Pain, Pain Duration, and Pain Disability met criteria for acceptable item-to-total correlation, change in alpha if item omitted, factor loading, skewness, IRT discrimination, and IRT threshold. All items met the criteria for utility in the CCDRS and were retained in the CCDRS. The revised TWSTRS-2 scale is included in the Supplemental Appendix.

### TWSTRS- PSYCH

Overall Cronbach’s alpha for the TWSTRS-PSYCH was 0.84 (Table 1). Items assessing Depression, Loss of Interest, Discomfort, and Anxiety met criteria for acceptable item-to-total correlation, change in alpha if item omitted, factor loading, skewness, IRT discrimination, and IRT threshold and were retained in the CCDRS. Items assessing Panic and Afraid of Going Outside met all criteria except for skewness. The skewed distribution appears to be the result of the high percentages of zero scores for Panic (88%) and Afraid of Going Outside (82%). The TWSTRS-PSYCH scale is included in the Supplemental Appendix.

### Combined TWSTRS-2 and TWSTRS-PSYCH

Overall Cronbach’s alpha for the combined TWSTRS2 (after removing items assessing anterocollis, retrocollis, lateral shift, sagittal shift, head tremor, and effect of a sensory trick) and TWSTRS-PSYCH was 0.88. All items met criteria for acceptable item-to-total correlation, change in alpha if item omitted, skewness, IRT discrimination, and IRT threshold. Factor analysis revealed a satisfactory four-factor solution with items assessing motor severity, disability, pain, and psychiatric manifestation loading on separate factors (all factor loadings > 0.40; Table 2).

### CDIP-58

Overall Cronbach’s alpha for the CDIP-58 was 0.98. The CFA of the eight-factor solution of the original CDIP-58 resulted in a CFI of 0.97 with a RMSEA of 0.07 and a model fit chi-square of 48.96 ( $P < 0.0005$ ) using the data from the current study. Thus, the prespecified eight-factor structure was confirmed.

## Discussion

This study demonstrates that the CCDRS assesses distinct components of CD and can be applied as a complete scale or used in a modular format. The current study provides a realistic picture of the clinimetric properties of this scale and each of its modules, and allows the deletion of items that do not demonstrate clinical utility.

The revised motor severity subscale of the TWSTRS-2 demonstrated that certain items (anterocollis, retro-

**TABLE 2.** Factor solution for combined TWSTRS-2 and TWSTRS-PSYCH after deleting TWSTRS-2 Severity items not meeting criteria for inclusion in the CCDRS

Item	Factor			
	1	2	3	4
Rotation				0.41
Laterocollis				0.51
Shoulder elevation				0.53
Duration				0.62
Range of movement				0.42
Time midline				0.63
Work disability		0.59		
ADL disability		0.52		
Driving disability		0.52		
Reading disability		0.80		
Television disability		0.75		
Outside disability		0.63		
Pain at best	0.76			
Pain at worst	0.84			
Pain at usual	0.92			
Pain duration	0.82			
Pain disability	0.67			
Depression			0.68	
Loss of interest			0.70	
Discomfort in public			0.58	
Anxiety			0.71	
Panic attack			0.61	
Fear of outside			0.62	

All factor loadings < 0.40 are not shown in the table.

collis, lateral shift, sagittal shift, head tremor, and effect of sensory trick) had multiple indicators of poor utility on both CCT and IRT analyses. The reasons for the lack of utility of these items are varied. Anterocollis, retrocollis, lateral shift, and sagittal shift ratings had highly skewed distributions, suggesting possible floor effects. Head tremor and effect of sensory trick had more normal-shaped distributions. However, these items had low item-to-total correlations and increased the alpha if omitted. Furthermore, the low factor loading of these items indicates that they may not directly contribute to overall CD severity in contrast to the other items, although these may be features of the disorder. Hence, these items were deleted from the rating of motor severity, resulting in a simplified scale that can be used efficiently in a clinical study (Supplemental Appendix).

The TWSTRS-2 disability subscale, which was unchanged from the standard TWSTRS, was not revised and had good reliability and content validity. The TWSTRS-2 pain subscale was revised, removing the mathematical manipulations (the multiplication of the usual level of pain by 2 and eliminating the division of the pain scores by 4) and was found to be reliable and valid. The first psychiatric screening tool for CD, TWSTRS-PSYCH (Supplemental Appendix), demonstrated good clinimetric properties. The CDIP-58,

which has previously been assessed for reliability and validity using a different scale development technique, was found to have acceptable internal consistency and a confirmed factor structure of eight factors. Inclusion of the CDIP-58 provides a patient-reported measure of the impact of CD on quality of life that is distinct from information provided by the other scales in the CCDRS.

Although many rating scales have been developed to evaluate CD, none has been comprehensive.<sup>10,15,40,41</sup> The CCDRS includes measures for motor severity, disability, pain, psychiatric disorders, and quality of life measures. Each of these domains may be affected in CD and contribute to overall severity of the condition. The reduction in total items in the TWSTRS-2 motor severity subscale based on these results will allow for easier use. Though the deleted items may be useful as descriptors for CD, these items do not contribute to the overall assessment of CD severity.

The results of the factor analysis for the modified TWSTRS-2 and TWSTRS-PSYCH suggest that the scores of the four subcomponents (motor severity, disability, pain, and psychiatric concerns) can be used either as independent measures or summarized into a single measure of CD impairment. The previously defined factor structure of the CDIP-58 was confirmed in the present analysis.

The CCDRS provides a tool that allows an assessment of all aspects of CD and can be used in modular format. This study provides the framework for development of rating scales that can be used to assess the varied clinical aspects of focal dystonias involving other body regions. As new therapeutic modalities become available for the treatment of focal dystonias,<sup>42</sup> it is critical that validated outcome measures capture not only the motor features, but also those related to psychological disorders and impact on quality of life. ■

**Acknowledgments:** This study is a part of the Dystonia Coalition (NS065701), which is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded through collaboration between NCATS and the National Institute of Neurological Disorders and Stroke. The Dystonia Coalition's program includes clinical features, natural history, a DNA repository, and the development of validated rating scales for focal dystonias. The Dystonia Study Group provided additional funding. The Dystonia Medical Research provided coordination of study sites. The authors also acknowledge the coordinators at each of the sites: Tracy Waliczek (Rush), Mary Louise Weeks (Emory), Emily Muller, Sara Lewis (Beth Israel Medical Center); Katie Holmes (University of Maryland); Christine Hunter, Lea Kiefer (Baylor College of Medicine); Laura Wright, Lin Yang (Washington University); Matthew Grana (University of Rochester); Brandon Rothberg (University of Toronto); Kyle Rizer (University of Florida); Amy Duffy (Mayo Clinic of Arizona, Scottsdale).

## References

- Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. *Neurology* 1991;41:1088-1091.
- Bhidayasiri R. Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. *Parkinsonism Relat Disord* 2011;17(Suppl 1):S20-S24.
- Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. *Mov Disord* 1991;6:119-126.
- Moraru E, Schnider P, Wimmer A, et al. Relation between depression and anxiety in dystonic patients: implications for clinical management. *Depress Anxiety* 2002;16:100-103.
- Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. Psychiatric comorbidity in patients with spasmodic torticollis. *J Psychosom Res* 1998;44:687-690.
- Queiroz MR, Chien HF, Barbosa ER. Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital. *Arq Neuropsiquiatr* 2011;69:900-904.
- Kuyper DJ, Parra V, Aerts S, Okun MS, Kluger BM. Nonmotor manifestations of dystonia: a systematic review. *Mov Disord* 2011;26:1206-1217.
- Odergren T, Tollback A, Borg J. Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. *Scand J Rehabil Med* 1994;26:191-195.
- Gudex CM, Hawthorne MR, Butler AG, Duffey P. Effect of dystonia and botulinum toxin treatment on health-related quality of life. *Mov Disord* 1998;13:941-946.
- Lindeboom R, Brans JW, Aramideh M, Speelman HD, De Haan RJ. Treatment of cervical dystonia: a comparison of measures for outcome assessment. *Mov Disord* 1998;13:706-712.
- Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. *Neurology* 1998;50:1461-1463.
- Hilker R, Schischniaschwili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. *J Neurol Neurosurg Psychiatry* 2001;71:193-199.
- Muller J, Kemmler G, Wissel J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. *J Neurol* 2002;249:842-846.
- Camfield L, Ben-Shlomo Y, Warner TT; Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. *Mov Disord* 2002;17:838-841.
- Albanese A, Sorbo FD, Comella C, et al. Dystonia rating scales: critique and recommendations. *Mov Disord* 2013;28:874-883.
- Tsui JK, Eisen A, Stoessel AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet* 1986;2:245-247.
- O'Brien C, Brashear A, Cullis P, et al. Cervical dystonia severity scale reliability study. *Mov Disord* 2001;16:1086-1090.
- Consky E, Lang, AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. *Therapy with Botulinum Toxin*. New York: Marcel Dekker, Inc.; 1994:211-237.
- Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. *Mov Disord* 1997;12:570-575.
- Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. *J Pers Assess* 1996;67:588-597.
- Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. *Psychopathology* 1998;31:160-168.
- Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361-370.
- Herrmann C. International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. *J Psychosom Res* 1997;42:17-41.
- Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. *J Anxiety Disord* 2006;20:444-458.
- Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? *J Neurol Neurosurg Psychiatry* 2002;72:608-614.
- Rosenberg M. *Society and the Adolescent Self-Image*. Princeton, NJ: Princeton University Press; 1965.
- Skogseid IM, Malt UF, Roislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. *Eur J Neurol* 2007;14:1129-1137.

28. Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. *J Neurol Neurosurg Psychiatry* 2004;75:749-753.
29. Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). *Neurology* 2004;63:1629-1633.
30. Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC. The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? *Health Qual Life Outcomes* 2008;6:58.
31. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. *Neurology* 2006;67:2230-2232.
32. Comella C, Fox S, Bhatia K, et al. Development of the Comprehensive Cervical Dystonia Rating Scale: methodology. *Mov Disord Clin Pract* 2015;2:135-141.
33. Osborne J, Costello A. Sample size and subject to item ratio in principal components analysis. *Prac Assess Res Eval* 2004;9:1-12.
34. Hatcher L. *A Step-by-Step Approach to Using SAS System for Factor Analysis and Structural Equation Modeling*. Cary, NC: SAS Institute, Inc.; 1994.
35. Grousch R. *Factor Analysis*, 2 ed. Hillsdale, NJ: Erlbaum; 1983.
36. Yan L, Hicks M, Winslow K, et al. Secured web-based video repository for multicenter studies. *Parkinsonism Relat Disord* 2015;21:366-371.
37. DeVellis R. Classical test theory. *Med Care* 2006;44(11 Suppl 3):S50-S59.
38. Stout W. Psychometrics from practice to theory and back. *Psychometrika* 2001;67:485-518.
39. Bentler PM. Comparative fit indexes in structural models. *Psychol Bull* 1990;107:238-246.
40. Jost WH, Hefter H, Stenner A, Reichel G. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. *J Neural Transm (Vienna)* 2013;120:487-496.
41. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. *Mov Disord* 1997;12:100-102.
42. Jinnah HA, Hess EJ. Experimental therapeutics for dystonia. *Neurotherapeutics* 2008;5:198-209.

## Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.